Literature DB >> 21084473

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Surender Khurana1, Swati Verma, Nitin Verma, Corey J Crevar, Donald M Carter, Jody Manischewitz, Lisa R King, Ted M Ross, Hana Golding.   

Abstract

The impending influenza virus pandemic requires global vaccination to prevent large-scale mortality and morbidity, but traditional influenza virus vaccine production is too slow for rapid responses. We have developed bacterial systems for expression and purification of properly folded functional hemagglutinin as a rapid response to emerging pandemic strains. A recombinant H5N1 (A/Vietnam/1203/2004) hemagglutinin globular domain (HA1) was produced in Escherichia coli under controlled redox refolding conditions. Importantly, the properly folded HA1(1-320), i.e., HA1 lacking amino acids 321 to 330, contained ≥75% functional oligomers without addition of foreign oligomerization sequence. Site-directed mutagenesis mapped the oligomerization signal to the HA1 N-terminal Ile-Cys-Ile residues at positions 3 to 5. The purified HA1 oligomers (but not monomers) bound fetuin and agglutinated red blood cells. Upon immunization of rabbits, the oligomeric HA1(1-320) elicited potent neutralizing antibodies against homologous and heterologous H5N1 viruses more rapidly than HA1(28-320) containing only monomers. Ferrets vaccinated with oligomeric HA1 (but not monomeric HA1 with the N terminus deleted) at 15 and 3 μg/dose were fully protected from lethality and weight loss after challenge with homologous H5N1 (A/Vietnam/1203/2004, clade 1) virus, as well as heterologous clade 2.2 H5N1 (A/WooperSwan/Mongolia/244/2005) virus. Protection was associated with a significant reduction in viral loads in the nasal washes of homologous and heterologous virus challenged ferrets. This is the first study that describes the presence of an N-terminal oligomerization sequence in the globular domain of influenza virus hemagglutinin. Our findings suggest that functional oligomeric rHA1-based vaccines can be produced efficiently in bacterial systems and can be easily upscaled in response to a pandemic influenza virus threat.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084473      PMCID: PMC3020491          DOI: 10.1128/JVI.02107-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

2.  Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus.

Authors:  D C Powers; J E McElhaney; O A Florendo; M C Manning; C M Upshaw; D W Bentley; B E Wilkinson
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

3.  Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities.

Authors:  James Stevens; Ola Blixt; Laurel Glaser; Jeffery K Taubenberger; Peter Palese; James C Paulson; Ian A Wilson
Journal:  J Mol Biol       Date:  2005-11-18       Impact factor: 5.469

4.  Fusion mutants of the influenza virus hemagglutinin glycoprotein.

Authors:  R S Daniels; J C Downie; A J Hay; M Knossow; J J Skehel; M L Wang; D C Wiley
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

5.  Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals.

Authors:  Debby van Riel; Vincent J Munster; Emmie de Wit; Guus F Rimmelzwaan; Ron A M Fouchier; Albert D M E Osterhaus; Thijs Kuiken
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria.

Authors:  Shuo Shen; Geetha Mahadevappa; Hsueh-Ling Janice Oh; Boon Yu Wee; Yook-Wah Choi; Le-Ann Hwang; Seng Gee Lim; Wanjin Hong; Sunil K Lal; Yee-Joo Tan
Journal:  J Med Virol       Date:  2008-11       Impact factor: 2.327

7.  Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Authors:  Chih-Jen Wei; Ling Xu; Wing-Pui Kong; Wei Shi; Kevin Canis; James Stevens; Zhi-Yong Yang; Anne Dell; Stuart M Haslam; Ian A Wilson; Gary J Nabel
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

8.  A surface plasmon resonance assay for the binding of influenza virus hemagglutinin to its sialic acid receptor.

Authors:  D K Takemoto; J J Skehel; D C Wiley
Journal:  Virology       Date:  1996-03-15       Impact factor: 3.616

9.  Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

Authors:  Keyang Wang; Kathleen M Holtz; Karl Anderson; Richard Chubet; Wafaa Mahmoud; Manon M J Cox
Journal:  Vaccine       Date:  2005-11-10       Impact factor: 3.641

10.  Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

Authors:  Langzhou Song; Valerian Nakaar; Uma Kavita; Albert Price; Jim Huleatt; Jie Tang; Andrea Jacobs; Ge Liu; Yan Huang; Priyanka Desai; Gail Maksymiuk; Virginia Takahashi; Scott Umlauf; Lucia Reiserova; Rodney Bell; Hong Li; Yi Zhang; William F McDonald; T J Powell; Lynda Tussey
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

View more
  34 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Authors:  Surender Khurana; Jian Wu; Milena Dimitrova; Lisa R King; Jody Manischewitz; Barney S Graham; Julie E Ledgerwood; Hana Golding
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

3.  Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.

Authors:  Teen-Lee Pua; Xiao Ying Chan; Hwei-San Loh; Abdul Rahman Omar; Vidadi Yusibov; Konstantin Musiychuk; Alexandra C Hall; Megan V Coffin; Yoko Shoji; Jessica A Chichester; Hong Bi; Stephen J Streatfield
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

4.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Authors:  Kawsar R Talaat; Catherine J Luke; Surender Khurana; Jody Manischewitz; Lisa R King; Bridget A McMahon; Ruth A Karron; Kristen D C Lewis; Jing Qin; Dean A Follmann; Hana Golding; Kathleen M Neuzil; Kanta Subbarao
Journal:  J Infect Dis       Date:  2014-03-05       Impact factor: 5.226

5.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

6.  H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Authors:  Surender Khurana; Jian Wu; Nitin Verma; Swati Verma; Ramadevi Raghunandan; Jody Manischewitz; Lisa R King; Eloi Kpamegan; Steven Pincus; Gale Smith; Gregory Glenn; Hana Golding
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

7.  Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems.

Authors:  Felix W Santiago; Kris Lambert Emo; Theresa Fitzgerald; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2012-05-15       Impact factor: 3.641

Review 8.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

9.  Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

Authors:  Felix W Santiago; Theresa Fitzgerald; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

Review 10.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.